Abiotic anti-VEGF nanoparticle

Patent metadata

Field	Value
Publication number	US-11458107-B2
Application number	US-201716327898-A
Country	US
Kind code	B2
Filing date	Aug 25, 2017
Priority date	Aug 25, 2016
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

The present invention relates generally to compositions and methods comprising abiotic, synthetic polymers with affinity and specificity to proteins. The synthetic polymers are an improvement over biological agents by providing a simpler, less expensive, and customizable platform for binding to proteins. In one embodiment, the compositions and methods relate to synthetic polymers with affinity and specificity to vascular endothelial growth factor (VEGF). In one embodiment, the compositions are useful for treating diseases and disorders related to the overexpression of VEGF. In one embodiment, the compositions are useful for treating cancer. In one embodiment, the compositions are useful for detecting VEGF levels from biological samples. In one embodiment, the compositions are useful for detecting overexpression of VEGF from biological samples. In one embodiment, the compositions are used to diagnose cancer.

First claim

What is claimed is:

1. A composition comprising a pharmaceutically acceptable carrier and an abiotic, synthetic cross-linked polymer having affinity to vascular endothelial growth factor (VEGF), comprising:
N-isopropylacrylamide (NIPAm);
N-tert-butylacrylamide (TBAm);
N,N′-methylenebisacrylamide (Bis); and
a sulfated N-acetylglucosamine (GlcNAc), wherein the polymer comprises between 1% and 3% sulfated GlcNAc.

2. The composition of claim 1 , wherein the sulfated N-acetylglucosamine (GlcNAc) is selected from the group consisting of mono-sulfated positional isomer 3S-GlcNAc, mono-sulfated positional isomer 4S-GlcNAc, mono-sulfated positional isomer 6S-GlcNAc, and tri-sulfated 3,4,6S-GlcNAc.

3. The composition of claim 1 , wherein the polymer comprises between 30% and 70% NIPAm.

4. The composition of claim 1 , wherein the polymer comprises between 30% and 50% TBAm.

5. The composition of claim 1 , wherein the polymer comprises between 0% and 10% Bis.

6. The composition of claim 1 , wherein the polymer comprises 56.3% NIPAm, 40% TBAm, 2% Bis, and 1.7% tri-sulfated 3,4,6S-GlcNAc.

7. The composition of claim 1 , wherein the composition is a nanoparticle.

8. The composition of claim 1 , wherein the composition further comprises at least one therapeutic agent.

Assignees

• Univ California
• Miura Yoshiko
• Hoshino Yu
• Nishimura Yuri
• Oku Naoto

Inventors

• Shea Kenneth J
• Koide Hiroyuki
• Miura Yoshiko
• Hoshino Yu
• Nishimura Yuri
• Oku Naoto

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/785

  Polymers containing nitrogen · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K31/795

  Polymers containing sulfur · CPC title

• A61K9/5146 Primary

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides · CPC title